The use of frontline autologous stem cell transplantation (ASCT) for newly diagnosed multiple myeloma (MM) has been questioned due to the development of new drugs. However, as explained here by Laurent Garderet, MD, PhD, of Saint Antoine Hospital, Paris, France, it is thought that ASCT should not be delayed. Furthermore, Dr Garderet discusses whether double vs. single ASCT is more beneficial for patients, and what the results of the data for this, presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, may mean for the clinical management of MM.
Upfront ASCT for newly diagnosed multiple myeloma: double vs. single transplant
